Multiple Sclerosis Severity ScoreRichard Roxburgh, D. A. S. Compston, Shaun R. Seaman et al.|Neurology|2005Cited by 957
Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trialLudwig Kappos, Paul D. Crowe, Giancarlo Comi et al.|Nature Medicine|2000Cited by 515
Neurologic manifestations associated with COVID-19: a multicentre registryElodie Meppiel, Thibault Fraisse, Guillaume Baille et al.|Clinical Microbiology and Infection|2020Cited by 142
Aggressive multiple sclerosis (1): Towards a definition of the phenotypeEllen Iacobaeus, Emmanuelle Waubant, Georgina Arrambide et al.|Multiple Sclerosis Journal|2020Cited by 79
Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1bCH Polman, Ludwig Kappos, Mark S. Freedman et al.|Journal of Neurology|2007Cited by 75